32 results about "Drug resistant mutants" patented technology

Compositions and methods are provided for amplifying and or detecting nucleic acid targets using labeled polynucleotide probes and antiprobes that interact together and with complementary targets. Competitive thermodynamic interactions of these components result in signaling changes that indicate target frequency, and can provide error-checking functions that facilitate single base discrimination. These probe:antiprobe compositions enable real-time PCR detection, end-point detection and microarray detection of microbial species, drug resistant mutants, and cancer related variants. Some probe:antiprobe systems function as an internal probe, between two primers, and some function as a primer-probe. Some target sequences are discriminated or quantified by employing two probe:antiprobe systems to detect different aspects of the same template.; Systems are also provided that enhance target amplification and detection for specific single base variants. A probe may also be modified by introducing a base mismatch to increase thermodynamic discrimination of a correct versus incorrect target differing by a single base.

The present invention relates to 2-arylaminopyridine, pyrimidine or triazine derivatives and their preparation method and application. The 2-arylaminopyridine, pyrimidine or triazine derivatives can act on certain mutant forms of epidermal growth factor receptors, such as L858R activation mutants, delE746_A750 mutants, Exon19 deletion activation mutants and T790M drug-resistant mutants , and thus be used in the treatment and prevention of diseases and conditions. The 2-arylaminopyridine, pyrimidine or triazine derivatives can be used for the treatment and prevention of cancer. The present invention also relates to pharmaceutical compositions comprising 2-arylaminopyridine, pyrimidine or triazine derivatives, intermediates for the preparation of 2-arylaminopyridine, pyrimidine or triazine derivatives, and the use of 2-arylamino Methods of pyridine, pyrimidine or triazine derivatives for the treatment of diseases mediated by various forms of EGFR.

The invention discloses a mycobacterium tuberculosis drug-resistant mutant gene detection kit comprising: (1) a gene chip which has (i) a nucleotide probe, wherein the probe is a sequence of SEQIDNos: 1-31 or a complementary sequence of SEQIDNos: 1-31, (ii) a DNA sequence labeled with biotin points, wherein the sequence is SEQIDNO. 32, (iii) an IS6110DNA sequence of a mycobacterium tuberculosis complex, wherein the sequence is SEQIDNo. 33; (2) various primers used for amplifying DNA sequences in clinical samples, wherein the DNA sequences of the primers are SEQIDNos. 34-41. The kit of the invention detects the drug resistance of mycobacterium tuberculosis to rifampin and isoniazid, provides reference basis for the prevention and treatment of tuberculosis, and has significant meaning.

The invention provides a method for amplifying four genes of Botrytis cinerea and a multiplex PCR (polymerase chain reaction) primer set thereof, relating to the field of molecular biology. On the basis of drug-resistant mutant sites of known Botrytis cinerea p-benzimidazole, boscalid, iprodione, fenhexamid and many other bactericides, a PCR primer set for simultaneously amplifying four gene segments beta-tub, BsOS1, erg27 and SdhB is established. The extracted Botrytis cinerea genome can be directly used as a template and subjected to amplification by using the designed primer set to obtain the enriched four gene segments. The multiplex PCR process is used for the first time to simultaneously amplify the four drug-resistant mutant genes of Botrytis cinerea, thereby greatly reducing the workload for drug-resistant site detection in the later period. By optimizing the PCR reaction system, the four gene segments are amplified in one PCR process.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 4,6-pyrimidine diamine compound and a preparing method and an application thereof; the 4,6-pyrimidine diamine compound is an N4,N6-(2,5-dialkoxy phenyl)-pyrimidine diamine compound or an N4-(2,5-dialkoxy phenyl)-N6-(3-alkoxy phenyl)-pyrimidine diamine compound, and in particular, alkoxy can be C1-C4 alkane. The 4,6-pyrimidine diamine compound can be used for broad-spectrum inhibition of the activity of an EGFR kinase and resisting of EGFR expressed tumor cell activity. The EGFR kinase is a wild-type or drug-resistant mutant EGFR kinase, and provides a basis for new drug screening. And the synthesis method of the 4,6-pyrimidine diamine compound provided by the invention is simple in synthesis process and is in favor of industrialized production.

The invention belongs to the field of medicine preparation, and particularly relates to the application of bisindole compound FGFC1 in the preparation of anti-non-small cell lung cancer drugs. The anti-non-small cell lung cancer drug is an anti-human non-small cell lung cancer drug targeting EGFR. The EGFR sensitive and drug-resistant mutant cell lines are PC9 and H1975. The anti-non-small cell lung cancer drug is at least one of tablet, capsule, granule, drop pill, suspension, syrup, enteric-coated preparation, emulsion suspension and injection. The bisindole compound FGFC1 of the present invention not only has the potential to be developed into a new generation of anti-non-small cell lung cancer drugs targeting EGFR, but also has potential in the fields of targeted drugs, probe design and fluorescent biomarkers for non-small cell lung cancer. Value.

The invention relates to a reagent for diagnosing drug resistance of mycobacterium tuberculosis, in particular to a membrane strip and a kit for detecting drug resistant mutant genes of the mycobacterium tuberculosis. The membrane strip for detecting the drug resistant mutant genes of the mycobacterium tuberculosis fixes a specific oligonucleotide probe which is used for detecting the drug resistant mutant genes of the mycobacterium tuberculosis on a substrate. The kit for detecting the drug resistant mutant genes of the mycobacterium tuberculosis comprises the membrane strip which is fixed with the specific oligonucleotide probe used for detecting the drug resistant mutant genes of the mycobacterium tuberculosis and a primer of drug resistant relevant genes of specific amplification mycobacterium tuberculosis. The kit for detecting the drug resistant mutant genes of the mycobacterium tuberculosis can simultaneously detect various usual drug resistant mutant gene types on five genes such as rpoB, katG, inhA, embB and rpsL, is suitable for the diagnosis of tubercle bacilli to the drug resistance of tuberculosis resistant drugs such as rifampicin, retozide, ethambutol, streptomycin,and the like, and has the advantages of quick and accurate detection, large flux, and the like.

The invention relates to a diagnostic reagent of candida and particularly relates to a nucleic acid film strip and a kit capable of simultaneously performing identification of candida species and detection of gene mutation. The nucleic acid film strip for identification of candida species and detection of gene mutation comprises a substrate and nucleic acid probes immobilized on the substrate, wherein the nucleic acid probes comprise a nucleic acid probe used for identification of candida species and having base sequences shown in SEQ ID NO: 1-7, a nucleic acid probe used for detection of gene mutation of candida albicans and having base sequences shown in SEQ ID NO: 8-23 and an internal reference nucleic acid probe having a base sequence shown in SEQ ID NO: 24. The nucleic acid film strip and the kit are used for identification of the species and detection of drug-resistant mutant genes according to the gene sequences of candida, judging from molecular structure, results are accurate and reliable and the detection sensitivity is high; the detection time is short and the detection can be completed only just in eight hours.

The invention discloses an amplification primer for detecting a drug-resistant mutant gene of HCV (hepatitis c virus) 2a subtype NS5A, application and a detection method. The amplification primer fordetecting a drug-resistant mutant gene of HCV 2a subtype NS5A comprises a first amplification primer pair, wherein sequences of an upstream primer and a downstream primer in the first amplification primer pair are shown by SEQ ID NO:1 and SEQ ID NO:2 respectively. The amplification primer for detecting a drug-resistant mutant gene of HCV 2a subtype NS5A can be used for analyzing and studying the mutation condition of the HCV gene so as to provide reference for clinical study on drug resistance. When the amplification primer is adopted to perform detection and analysis such as PCR amplification, the effectiveness is high, the detection success rate can reach 100%, the reproducibility is high, and particularly, the minimum detection limit is low, thus the detection of a sample with low HCV RNA concentration is facilitated while the sensitivity is high.